News | July 09, 2021
Pfizer and BioNTech expects third dose clinical studies of COVID-19 vaccine in August
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
The partnership is a significant step in delivering advanced cancer therapies to patients.
Subscribe To Our Newsletter & Stay Updated
